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ABSTRACT 
Metastasis is one of the clinical parameters that has a strong negative influence on the 
prognosis of cancer patients. In recent years, significant advances have furthered our 
understanding of this process at the molecular and biological levels. This review will 
discuss recent discoveries relating to the earliest, intra-tumoral stages of metastasis in 
cancer cells, specifically focusing on: (i) the development of metastatic traits during 
primary tumorigenesis; (ii) intrinsic and extrinsic cancer cell programs associated 
with malignant traits; (iii) the intra-tumoral migration patterns of cancer cells and the 
dynamic roles played by the Rho/Rac GTPases and epithelial-mesenchymal 
transitions in this process; and (iv) the genetic strategies used by metastatic cancer 
cells to promote intra-tumoral cell migration and their subsequent escape to 
peripheral tissues. Finally, the therapeutic and diagnostic relevance of this 
information will be discussed, as well as potential future developments. 
 
ABBREVIATIONS USED (in alphabetical order) 
Ahr, aryl hydrocarbon receptor; Ddr1, Discoidin domain receptor 1; Dicer, enzyme 
capable of “dicing” double stranded RNAs; Dock, dedicator of cytokinesis; EMT, 
epithelial-mesenchymal transition; EM/MET, epithelial-mesenchymal/mesenchymal-
epithelial transition; Eph, tyrosine kinase receptor expressed in an erythropoietin-
producing hepatocellular cell line; Ephrin, Eph-receptor interacting protein; GAP, GTPase 
activating protein; GEF, guanosine nucleotide exchange factor; Hotair; homeobox 
transcript antisense RNA; Hoxd10, homeobox D10; IL, interleukin; MET, mesenchymal-
epithelial transition; MYBPH, myosin binding protein H; MMP, matrix metalloprotease; 
ncRNA, non-coding RNA; PTTG1, pituitary tumor-transforming 1; PyMT, polyomavirus 
middle T-antigen; RCP, Rab-coupling protein; Sec23a, Sec23 homolog A; TGF, 
transforming growth factor; VEGF, vascular endothelial growth factor; XIAP, X-linked 
inhibitor of apoptosis protein. 
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INTRODUCTION 
Metastasis, the biological process that encompasses the dissemination of cancer cells from 
the primary tumor and the subsequent formation of new tumor masses in peripheral tissues, 
is one of the main clinical parameters known to affect the prognosis of cancer patients 
nowadays.  Indeed, its detection in patients is usually associated with resistance to 
chemotherapeutic treatments, higher post-treatment recurrence rates, and poor cancer 
patient survival rates [1,2]. Thus, the understanding of the metastatic process at both the 
genetic and biological level is of utmost importance to develop more effective anti-cancer 
therapies. Metastasis can be subdivided into a number of distinct stages according to 
mechanistic and regulatory criteria (Fig. 1). The first stage occurs within the primary 
tumor, where subpopulations of cancer cells develop a metastatic phenotype and migrate 
through a densely-packed environment composed of extracellular matrix, cancer cells and 
stromal cells in order to exit the tumoral mass (Fig. 1, point 1). The second stage involves 
the dissemination of cancer cells away from the primary tumor via either lymph vessels 
(Fig. 1, point 2) or the vasculature (a process called intravasation: Fig. 1, point 3). 
Circulating cancer cells (Fig. 1, point 4) then adhere to the microvasculature and move 
across the vascular endothelial cell layer and the extracellular matrix of the peripheral 
tissue in a process generically referred to as extravasation (Fig. 1, point 5). Finally, the 
extravasated cells colonize the new peripheral niche, a process known as macrometastasis 
(Fig. 1, point 6). Despite the malignancy associated with the metastatic process, it is in fact 
highly inefficient as it is estimated that less than 0.5% of cells that enter the circulation 
eventually form metastases. Indeed, most of the circulating cells die upon extravasation to 
non-permissive peripheral tissues (Fig. 1, point 8). Less frequently, cancer cells enter a 
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dormant state in the peripheral niche either at the single-cell or micrometastasis stage (Fig. 
1, point 7). When appropriate growth conditions arise, these cells exit the dormant state to 
form a macrometastasis (Fig. 1, point 9). 
Recent reviews have focused on the history of the research carried out in this area, 
the conceptual frameworks that help understand the biological basis of this process, and the 
biological programs that regulate many of the stages of metastasis [1-5]. The present review 
will focus on issues specifically related to the earliest, intratumoral metastatic stages of 
cancer cells. Recent analyses of this particular phase of the metastatic process have shed 
light on the ontogeny of tumor metastasis, the necessary developmental and physiological 
conditions, and the biological programs that guide the overall metastatic process. These 
findings have also revealed new, and in some cases unexpected information about the 
migration of cancer cells within tumors, the regulation and role of Rho/Rac GTPases during 
cancer cell migration, and the dynamic roles of processes such as epithelial-mesenchymal 
transitions. Some of those findings also have significant potential to be translated into 
clinical applications, especially in the area of cancer diagnosis. 
 
The metastatic phenotype develops pre-selectively in the primary tumor mass 
Historically, two different models have been used to explain the ontogeny of metastasis. 
The “tumor-centric” model stated that all metastases originate from fully metastatic cells 
that are already present in the primary tumor. By contrast, the “multi-centric” theory 
postulated that cancer cells must undergo additional rounds of genetic alterations in 
peripheral niches to finally form the macrometastasis [5]. Although the latter model was at 
odds with standard Darwinian evolutionary theory, it conveniently explained a number of 
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clinical observations, such as the long-term dormancy of metastatic cancer cells in healthy 
tissues and the frequent cases of patients displaying metastasis with no obvious physical 
indications of primary tumors. The recent sequencing of primary tumors and metastases 
from cohorts of patients unequivocally tilted the balance in favor of the “tumor-centric” 
model [6-10]. Irrespective of the tumor type analyzed, these studies consistently 
demonstrated that: (i) metastases originate monoclonally from single cancer cells originally 
present in the primary tumor; (ii) the metastatic populations are characterized by more 
extensive genetic/genomic alterations than other cancer cells present in the primary tumor; 
(iii) metastasis-specific mutations are also detected in discrete and regionalized cell 
subpopulations present in the primary tumors of the same patients, indicating that no 
metastatic niche-specific mutations occur; and (iv) there is a closer genetic proximity 
between metastases obtained from the same organ than in those retrieved from distinct 
anatomic locations, suggesting that metastasis requires tissue-specific biological programs 
(see below). Collectively, these findings indicate that metastatic traits are fully acquired at 
the primary tumor stage and that metastases originate late in tumor development as a 
consequence of increased genomic instability, thereby requiring a significant period to fully 
develop in patients (Fig. 2).  
These observations have been applied to breast, pancreatic and prostate tumors, and 
will be probably extrapolated to other tumor types in coming years. If so, they will also 
influence the mechanistic interpretation of poorly characterized metastatic stages. For 
example, the acquisition of, and exit from, the dormant metastatic state will be better 
explained in terms of the absence/restoration of signaling cross-talk between the 
extravasated cancer cells and the microenvironment, rather than by the generation of new 
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mutations in dormant cancer cells. Indeed, the data currently available indicate that a 
number of signaling routes involved in cell adhesion, mitogenesis and stress responses 
affect metastatic cancer cell dormancy (for review, see [11]). Notwithstanding the above 
evidence, the possibility that metastatic cancer cells from other tumor types could undergo 
a second wave of mutations during the dormant state cannot be formally disregarded as yet, 
especially in dormant states theoretically compatible with the generation and subsequent 
expansion of new pro-growth mutations (i.e., micrometastases that are kept dormant due to 
a steady-state equilibrium between rates of proliferation and apoptosis). The sequencing of 
additional tumor types should clarify this issue in the near future. 
 
Intrinsic cancer cell programs associated with the metastatic phenotype 
The genetic relatedness of metastases obtained from the same peripheral location suggests 
that genetically programmed routes pre-determine the colonization of specific peripheral 
tissues by metastatic cells (Fig. 2). This concept is in accordance with the “soil and seed” 
hypothesis originally proposed by Stephen Paget in 1889 to explain the tissue-specific 
dissemination of metastatic cancer cells [5]. This idea was recently confirmed following the 
identification of gene and ncRNA signatures directly associated with the tropism of 
metastatic cancer cells towards peripheral tissues, such as the brain, lung and bone [12-20]. 
The functional dissection of these signatures also led to the discovery of specific proteins 
and ncRNAs that play critical roles in step- and tissue-specific metastatic stages, including 
intravasation and extravasation, as well as the subsequent fitness of cancer cells in 
peripheral tissues [12-19,21-25] (Fig. 3). 
Despite the large heterogeneity of biological programs that regulate the tissue
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specific tropism of metastatic cancer cells, the pro-metastatic proteins and/or microRNAs 
can be subdivided in two main subclasses: the “metastastic maintenance” and the 
“metastatic virulence” groups. The former are regulatory factors (proteins and microRNAs) 
that play proactive roles in both primary tumorigenesis (i.e., proliferation, angiogenesis) 
and specific stages of the overall metastatic process (v.gr., vascular permeability, 
extravasation). The latter represent pro-metastatic factors that, surprisingly, have no 
significant role in primary tumorigenesis. 
While the enrichment of genes that maintain the metastatic state in the primary 
tumor is conceptually logical in terms of the expansion of mutations conferring an 
advantageous phenotype within the overall cell population, the appearance of “virulent” 
pro-metastatic factors is more challenging. According to standard population genetics 
dynamics, cells expressing these factors would be progressively out-competed by cell 
clones containing genetic programs associated with better fitness within the primary tumor. 
Thus, how do cell clones harboring these gene signatures become enriched in the primary 
tumor? Although the answer to this question remains unclear, a recent study by Joan 
Massagué’s group revealed that a significant percentage of the cells in the primary tumor 
may not actually originate in the tumor itself but rather, they are “prodigal son”-like cells 
that have returned to the primary tumor from the bloodstream or from peripheral metastatic 
nodules [26]. These cells were proposed to be the source of the virulence gene signatures 
present in the primary tumors, as they have undergone peripheral selection that favors the 
enrichment of cell clones carrying pro-metastatic mutations. Given the large estimated 
percentage of these “returning” cells in experimentally-induced tumors, this process was 
assumed to be genetically programmed. Indeed, the reseeding of the tumor by cancer cells 
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is driven by the secretion of chemotactic factors (IL6, IL8) by the primary tumor, and it 
requires the upregulation of an extravasation-like program in the returning cancer cells 
through the secretion of MMPs and the expression of cytoskeletal components [26]. 
 
 
Extrinsic cancer cell programs affect the latency and efficiency of metastasis 
Although the metastatic process was traditionally viewed from a purely cancer cell point of 
view, the acquisition of a metastatic phenotype is now understood as a dialectic process 
affected by the pre-tumoral developmental history of cancer cells and by ancillary 
influences emanating from diverse stromal cell types. These influences affect the speed at 
which metastatic traits can develop within the tumor, the effective migration/intravasation 
of the metastatic cells, and even the survival of the metastatic cells in distant peripheral 
tissues (Fig. 4). One of the best examples of the influence of cancer cell ontogeny on the 
development of the metastatic phenotype is the high and rapid rate of metastasis in 
melanoma, which can be explained by the strong expression of the EMT-promoting Slug 
transcriptional factor [27] in normal melanocytes [28]. The progression to the metastatic 
state in solid tumors also depends on the cooperative action of stromal cells, such as 
myoepithelial cells, adipocytes, immunosuppressive T-regulatory lymphocytes, myeloid-
derived suppressor cells, Gr1+ monocytes, M2 subtype macrophages and platelets [29,30] 
(Fig. 4). In the case of early stages of intratumoral metastasis, these non-tumor cells 
promote autocrine and paracrine loops that favor tumor progression [31,32], cancer cell 
motility [31-37], angiogenesis [38], and the evasion of anti-tumoral cytotoxic T-
lymphocytes and natural killer cells [29,30,39]. Intratumoral stromal cells also favor extra-
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tumoral stages of metastasis by activating TGFβ-dependent signaling, which in turn 
stimulates pro-permeability vascular programs that promote the intravasation and 
extravasation of cancer cells in specific peripheral tissues [17]. These cells also favor the 
secretion of extracellular matrix proteins by tumor cells that, upon release into circulation 
and attachment to peripheral tissues, create “pro-metastatic niches” in healthy tissues before 
the arrival of the metastatic cells [40] (Fig. 4). 
Stromal cells are attracted to the tumor through passive signaling events that are 
triggered by pathological or extracellular matrix induced inflammation, and/or intratumoral 
hypoxia [29,30,41,42]. Alternatively, they can be actively enticed towards the tumor by the 
active secretion of chemokines and by the extracellular ligands expressed by cancer [41-
43], tumor-associated stromal and hematopoietic cells [35,37,44-46], and/or endothelial 
cells [38] (Fig. 4). Although these ancillary events would appear to be activated at 
relatively advanced stages of primary tumor development, this may not be the case for all 
tumor types. For example, sequencing of the genomes of hepatocellular carcinomas has 
shown that the “first wave” of mutations that originate in these tumors are related to the 
generation of a pro-inflammatory environment [47]. Moreover, in some cases the “pro-
metastatic” inflammation may be generated by chance by a tumor non-autonomous 
program, due to changes in the normal environment in which the initial cancer cells are 
found (Fig. 4). This process has been recently demonstrated in the post-partum mammary 
gland, whereby the intrinsically high levels of extracellular matrix deposition, fibrosis and 
acute inflammation typically associated with that physiological state favor the acquisition 
of both migratory and invasive properties by breast cancer cells [48]. This physiological 
conditioning probably explains the poor prognosis associated with postpartum breast 
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tumors detected in women [49]. 
 
Cancer cells undergo dynamic changes in migration patterns during metastasis 
In addition to the acquisition of genetic traits that prepare metastatic cells for the biological 
and physical challenges they face outside the primary tumor, these cells must acquire the 
migratory and invasive capacity required for migration within the tumor, as well as for 
intravasation, extravasation and migration in the new peripheral niche. Although it was 
generally assumed that cancer cells migrated individually within tumors, recent evidence 
revealed that cancer cells adopt collective and single cell migratory behaviors inside 
tumors, in a dynamic and reversible manner. Furthermore, the signaling routes involved in 
these processes has altered previously held paradigms about the role played in this process 
of Rho/Rac GTPases, a Ras subfamily with key roles in the control of cytoskeletal 
dynamics [50,51]. Thus, in addition to the standard role of specific members of this 
subfamily in the generation of different cytoskeletal structures, such as filopodia (Cdc42), 
membrane ruffles (Rac1), lamellipodia (Rac1) and stress fibers (RhoA) [50,51], we now 
know that they also contribute to the acquisition of specific cell shapes and intercellular 
adhesion mechanisms. These processes are essential to explain how tumor cells migrate 
both within the tumor and when leaving the primary tumor mass. 
The migratory behavior of cancer cells within the tumor is conditioned by the 
presence of extracellular signals in the surrounding environment. In inner regions of tumors 
that lack the factors that induce EMT, tumor cells tend to migrate in large multicellular 
clusters that follow the tracks in the extracellular matrix created by leading fibroblasts (Fig. 
5, collective 1). This movement is coordinated by the activation of fibroblast and cancer 
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cell specific signaling pathways. The movement of the leading fibroblast is driven by active 
RhoA/Rock-dependent actomyosin contractility, α3/α5-integrin signaling, force-mediated 
matrix remodeling and MMP activity (Fig. 5). By contrast, the trailing cancer cells depend 
on Cdc42-mediated actomyosin contractility [52] and on “gluing forces” that favor the 
cohesion of the entire migratory cell cluster (Fig. 5). This cohesion is generated by two 
independent mechanisms. On one hand, actomyosin contractility is inhibited in areas of 
cell-cell contact within the cell cluster, a process that involves the E-cadherin/Ddr1/RhoE-
dependent inactivation of Rho family GTPases [53] (Fig. 5). On the other hand, the cell-
cell contact zones are further glued together by the interaction of the EphA tyrosine kinase 
receptor and one of its ligands, eprhin-B2, both of which are present in adjacent cells of the 
cluster [54] (Fig. 5). This type of movement is essential for the dissemination of cancer 
cells to lymph nodes, although it is not required for the intravasation of cancer cells [55]. 
The migratory cancer cell cluster becomes scattered upon reaching peripheral tumor 
cell areas enriched with extracellular signals that favor EMT (Fig. 5). Depending on the 
signal transduction route and the Rho/Rac GTPase engaged at that moment, the scattered 
cancer cells can acquire an amoeboid- or mesenchymal-like migratory behavior (Fig. 5). 
The former involves high levels of RhoA/Rock-triggered actomyosin contractility that 
induces the moving cell to adopt a round, globular shape, while the latter is characterized 
by cells with a fibroblast-like morphology and is dependent on high levels of Rac1 activity, 
high MMP levels and weak actomyosin contractility [56] (Fig. 5). Cells can fluctuate 
between these amoeboid and mesenchymal migratory patterns by modulating their levels of 
RhoA, Rac1 and Cdc42 [57-59] (Fig. 5). Current data indicate that the movement of single 
cells within the tumor is critical for both the intravasation and extravasation stages [55,60].  
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Cancer cells have also been proposed to adopt other migratory behaviors. For 
example, in the early stages of PyMT-induced breast cancer, cancer cells exhibit a novel 
form of Rac1-dependent collective migration that, unlike that described above, does not 
rely on leading fibroblasts [61] (Fig. 5, collective 2). In these moving clusters, cancer cells 
lose their polarity but they conserve other epithelial features, such as the correct distribution 
of E-cadherin and β-catenin in the plasma membrane [61]. Interestingly, cells in the leading 
edge of the moving cluster do not appear to project filopodia or undergo membrane ruffling 
during the migration process [61]. This type of movement seems to be “inherited” from the 
migratory pattern seen in non-transformed mammary epithelial cells during pubertal 
mammary gland morphogenesis [61]. Additional data indicate that metastatic cells from 
different tumors may also display different migratory behaviors outside the primary tumor. 
Indeed, a recent study reported that melanoma and lung adenocarcinoma cells follow 
different migratory pathways once extravasated into the brain: the former move in close 
physical contact with the microvasculature, while the latter migrate at a distance from and 
totally independently of the brain blood vessels [62]. It is likely that the use of sophisticated 
intravital microscopy techniques in additional animal-based tumor models will reveal new 
migratory behaviors in cancer cells at both the primary tumor and peripheral sites. 
 
Cancer cells deregulate Rho/Rac-dependent routes through different mechanisms 
Given the important role of Rho/Rac proteins in tumorigenesis and cancer cell migration, it 
is unsurprising that cancer cells use multiple strategies to deregulate their activity. In 
addition to the standard activation by gene amplification or autocrine/paracrine loops, 
recent studies have shown that the levels of Rho/Rac GTPases, Rho/Rac activators and/or 
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effectors, can be increased in cancer cells by impeding ubiquitination-dependent protein 
degradation [63-65], stimulating specific transcriptional factors (c-Myc, PTTG1, Ahr) [66-
68], epigenetically silencing negative regulatory molecules (e.g., MYBPH, a gene encoding 
an inhibitory Rock binding protein) [69], inactivating tumor suppressor proteins (e.g., 
Hoxd10) via the overexpression of microRNAs (miR-10b) or long ncRNAs (Hotair) 
[22,70], or by depleting anti-metastatic microRNAs (miR-31) [23,24]. Perhaps the most 
dramatic mechanism used by cancer cells to upregulate Rho/Rac-dependent pathways is 
through the direct alteration of microRNA synthesis following Dicer elimination in cancer 
cells. The loss of Dicer may be achieved by transcriptional repression (via the mutant p53-
dependent inactivation of Tap63, a p53 related protein that promotes Dicer gene 
transcription) [71] or by miR-103/107-mediated degradation of the Dicer transcript [72]. 
Whatever the means, this is probably quite a useful stratagem, as it is estimated that ≈20% 
of all the cellular microRNAs fulfill motility- or EMT-related functions [73]. The signaling 
output of Rho/Rac-dependent routes can also be fine tuned by other regulatory 
mechanisms, including: the sumoylation of Rac1, which favors the sustained activity of this 
GTPase [74]; c-Myc triggered transcriptional feedback loops that antagonize specific 
downstream effects of RhoA [75]; and cytoskeletal-dependent signaling loops that favor the 
generation of further waves of active Rac1 [76]. It is expected that additional regulatory 
mechanisms will be revealed as we extend our understanding of the gene signatures and 
biological programs associated with cell motility and invasion in different cell types. 
 
The cancer cell migratory machinery is connected to other tumorigenic routes 
In addition to altering the functional status of Rho/Rac-related pathways, cancer cells can 
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manipulate the motility/adhesion machinery using signaling mechanisms that, 
unexpectedly, involve tumor suppressors, vesicle trafficking regulators or apoptosis-related 
proteins. For example, mutant p53 favors cell migration, loss of directionality and 
metastasis by promoting the active recycling of the EGF receptor and of α5/β1 integrins at 
the leading edge of migrating cancer cells.  This function of mutant p53 is mediated by the 
binding to, and subsequent inactivation of the p53-related TAp53 protein [77]. Although 
the mechanism is not fully understood, it has been shown that the inactivation of TAp63 
promotes the interaction of α5/β1 integrins with RCP, a Rab-coupling protein involved in 
membrane trafficking events.  Consistent with this model, cancer cells lacking TAp63 show 
the same migratory phenotype than mutant p53-expressing cells. Conversely, the pro-
migratory and pro-metastatic effects of mutant p53 can be eliminated in cancer cells by 
overexpressing TAp63 or depleting RCP [77].  The participation of the vesicle recycling 
machinery in the migration of cancer cells is further highlighted by the role of Rab25 and 
Rab5 in this process, two intracellular trafficking-related GTPases that promote the 
recycling of vesicular α5/β1-integrin (Rab25) and Rac1 proteins (Rab5) back to the leading 
edge of cancer cells [78,79]. Accordingly, Rab family genes and RCP are frequently 
amplified in specific human tumors [77,80]. In the case of the apoptotic machinery, the 
survivin/XIAP complex can promote migration by inducing the NFκB-dependent 
expression of fibronectin and, as a consequence, sustained β1-integrin, FAK and Src 
signaling in both cancer and stromal cells [81]. Given the functional connections between 
the aforementioned pathways, these data suggest that the deregulation of a single regulatory 
step has a significant impact on the overall activity of these cytoskeletal-related routes 
through the indirect stimulation of parallel pathways. Such a possibility could be further 
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assessed in future studies using standard gain- and loss-of-function approaches. 
 
Fluctuations between epithelial and mesenchymal traits are important for efficient 
metastasis 
Characterization of the biological processes that favor cell motility has provided significant 
insight into the role and regulation of EMT in the context of tumors. As discussed above, it 
is now clear that this process is not constitutively activated in tumor cells but rather, it 
fluctuates dynamically during the migration of cancer cells depending on regional and 
extracellular cues that are heterogeneously distributed within the tumor. Likewise, recent 
data have shown that epithelial-mesenchymal/mesenchymal-epithelial transitions 
(EM/MET) also occur in circulating cancer cells and within the peripheral niche [82]. This 
ability to dynamically regulate EM/MET is also important for the fitness of metastatic cells, 
because it has been shown that cancer cells that cannot revert to an epithelial state upon the 
extravasation step cannot generate metastasis [55,83,84].  All those results suggest that the 
mesenchymal and epithelial state can contribute to metastasis in function of the location of 
the cancer cell.  What are these pro-metastatic properties? In the case of EMT, recent 
reports indicate that its contribution to metastatic dissemination is more complex than 
simply promoting cell scattering via the downregulation of E-cadherin and cell-cell 
junction-related proteins [27]. Consistent with this view, it has been shown that the 
mesenchymal state is directly associated with the acquisition of undifferentiated, stem cell-
like phenotypes by cancer cells [85-89], the induction of angiogenesis [90] and the 
inhibition of anti-tumoral lymphocytes [42] (Fig. 6). The pro-angiogenic effects are 
mediated by the transcriptional activation of the Vegf gene by β-catenin, a transcriptional 
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factor released from the plasma membrane upon the loss of E-cadherin [90]. The 
immunosuppressant effects are triggered by Snail1-dependent expression of 
thrombospondin1, an extracellular matrix protein that stimulates a subclass of 
immunosuppressor lymphocytes (regulatory T cells) and that inhibits antigen-presenting 
cells [42]. As indicated above, the acquisition of mesenchymal traits also favors 
intravasation over lymph node dissemination and the extravasation step [55,60,82]. Recent 
observations have also illustrated some of the pro-metastatic properties induced by MET. 
For example, miR-200c, a microRNA that maintains epithelial morphology by inhibiting 
the expression of Zeb family transcripts, is important to block the secretion of anti-
metastatic soluble factors (i.e., Igfbp4, TinaglI1) by the extravasated cancer cells.  To carry 
out this Zeb- and E-cadherin-independent function, mir-200c targets the transcript for 
Sec23a, a protein involved in the anterograde transport of proteins from the endoplasmic 
reticulum to the Golgi apparatus [84]. Other members of the same microRNA family (e.g., 
miR-200a) are involved in promoting resistance to oxidative stress [91], a property that 
may be advantageous for cancer cells both in the primary tumor and in specific peripheral 
niches. Since the study of the pro-metastatic advantages conferred by the MET is still in its 
infancy, it is likely that additional functions will be revealed in the near future. 
Multiple controls have developed during evolution to ensure that the EMT program 
is only activated under very specific physiological or developmental conditions. Thus, the 
activation of this program poses a significant challenge to cancer cells. In addition to the 
indirect activation of the program via EMT-promoting ligands secreted by cancer cells and 
stromal cells (e.g., TGFβ), recent reports have shown that EMT can be activated by 
deregulating EMT signaling elements at the transcriptional [25,71], epigenetic/chromatin 
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remodeling [70,92-94], non-coding (nc)RNA [25,72,95,96], microRNA biosynthesis (i.e., 
elimination of Dicer mRNA) [71,72] and protein translation [97] levels (Fig. 6). The 
mechanism(s) used by cancer cells to overcome this prima facie constitutive activation of 
the EMT program in order to restore the pro-metastatic epithelial state upon extravasation 
into peripheral niches remains unclear. 
 
Potential clinical value of early pro-metastatic factors and gene signatures 
What are the potential clinical applications of this new information? The answer to this 
question probably depends on what we want to achieve. The use of signaling elements 
involved in the early intratumoral stages of the metastatic cascade does not seem 
particularly valuable from a therapeutic point of view. This is because the most clinically 
relevant issue in patient treatment is how to tackle already established metastases rather 
than how to prevent them. However, some of the identified early pro-metastatic factors may 
be therapeutically useful if they play additional roles in maintaining macrometastasis in 
peripheral tissues.  For example, it has been shown that the forced re-expression of miR-31, 
a microRNA whose downregulation is important in both early and late metastatic stages of 
cancer cells [23,24](Figs. 3), can induce the regression of lung macrometastasis in vivo 
[98]. This result underscores the importance of carrying out similar studies with other pro-
metastatic factors using experimental conditions that mimic as close as possible clinically 
relevant conditions. 
The most direct and rapid application of the information discussed here will 
probably be through the development of new diagnostic tools. Indeed, many metastasis-
linked gene and ncRNA signatures have been identified and have enough predictive power 
Bustelo (2012) 
 18 
to stratify patients in terms of survival, disease recurrence and of the development of 
general or tissue-specific metastases. These signatures could be easily reformatted into 
either small/medium complexity microarrays, or quantitative reverse transcription-PCR 
kits, to analyze biopsies from cancer patients. Some of these signatures have in fact already 
reached a clinical setting in microarray format [99,100]. The application of these new 
genetic diagnostic kits will be important to ensure the selective administration of usually 
harsh anti-tumor therapies only to patients whose tumor biopsies reveal “metastatic-
friendly” gene signatures. 
 
CONCLUSIONS AND OUTLOOK 
The data presented above highlight the significant advances that have been made in our 
understanding of the origin, regulation and mechanics of the earliest stages of the metastatic 
process in recent years. We have also unraveled many aspects of the biological programs 
associated with each metastatic stage, such as the manner in which cancer cells migrate 
within and beyond the original tumor mass, and the genetic alterations that contribute to 
form more robust metastases. Finally, we have learnt new information about the pro-
metastatic functions of Rho/Rac GTPases, tumor suppressors, apoptotic regulators, and the 
EM/ME transitions.  Most of those advances are potentially relevant for the development of 
new therapeutic and diagnostic tools in the near future.  Despite this progress, much work 
lies ahead. For example, as most research to date has focused on very specific cancer 
subtypes (i.e., breast, lung), little is known about the pro-metastatic regulatory and effector 
routes in the majority of solid tumors. Similarly, because the migratory patterns of cancer 
cells have been mainly studied in cancer cell lines derived from specific tumor types, it 
Bustelo (2012) 
 19 
remains unclear how primary metastatic cancer cells migrate in vivo. In the near future, the 
combination of signaling, high-throughput technologies and cell/animal models should help 
to identify new regulatory mechanisms and genetic alterations associated with this process. 
Finally, studies specifically designed to obtain clinical rather than pre-clinical information 
will be essential to push this field into the therapeutic arena. The conceptual, biological and 
technological developments achieved in recent years will undoubtedly facilitate such 
studies in the future. 
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FIGURE 1. Summary of the stages followed by cancer cells to colonize peripheral tissues. 
Those include the pre-metastatic stages that take place in the primary tumor (step 1) and the 
subsequent stages of lymph node infiltration (step 2), intravasation (step 3), dissemination 
through the circulatory system (step 4), extravasation (step 5), macrometastasis formation 
(step 6), abortive metastasis (step 8), acquisition of a dormant state (step 7), and exit from 
dormancy (step 9). In the case of death in the peripheral tissue, we have included two 
different possibilities: (i) death of a cancer cell (shown in purple) with a proper 
extravasation program but lacking the right biological package to survive inside the lung 
parenchyma. (ii) death of a cancer cell (shown in green) that despite having the appropriate 
biological programs for extravasation and intraparenchymal growth, undergoes apoptosis 
due to deficient interactions with other cues present in the stroma of the peripheral tissue. 
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For the sake of simplicity, we only illustrate the colonization of the lung by metastatic cells. 
The metastasis of cancer cells to other peripheral tissues may have different requirements. 
For example, the extravasation of cancer cells into the liver and bone does not appear to 
require specific biological programs due to the highly fenestrated nature of the vasculature 
in these tissues. Information about the cell types included in the figure is displayed in the 
inset at the bottom of the figure. Further details are provided in the main text. 
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FIGURE 2. The evolution of metastatic traits in a primary tumor. According to recent data, 
the metastatic phenotype is acquired in late stages of cancer development due to increased 
genetic instability. Depending on the genetic and biological programs of the different 
metastatic clones, they will only disseminate to and successfully colonize a specific 
spectrum of peripheral tissues. However, most cells do not have the right biological 
program to survive through all stages, leading to the death of the vast majority of 
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intravasated cancer cells. Current estimates indicate that the main selection step occurs 
upon the extravasation of cancer cells into the peripheral tissue. However, extravasated 
cells with the appropriate biological program to colonize peripheral tissues may enter a 
dormant state if they cannot find or induce permissive biological conditions for metastatic 
growth.  
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FIGURE 3. Some of the regulatory molecules known to affect the metastatic cycle of 
breast tumors. The main stages of metastasis are shown at the top. The peripheral tissues 
depicted include brain, lung and bone. Positive and negative regulators are shown in black 
and red, respectively. Please note that some molecules may have both positive and negative 
effects in different metastatic stages (e.g., the miR-200 family). A question mark indicates 
no available information, and lack of progress in this area has been mainly due to the 
technical challenges associated with analyzing metastatic stages inside the brain. The 
extravasation stage of metastatic cells to bone does not pose a significant biological 
challenge, as the bone vasculature is fenestrated and contains only endothelial cells with no 
associated mural cells. In normal conditions, such histological structure favors the 
continuous movement of hematopoietic cells in and out of the bone marrow.  Angpl4, 
angiopoietin-related protein 4; CCL2, chemokine (C-C motif) ligand 2; Cox2, cyclo-
oxygenase 2; CTGF, connective tissue growth factor; FAK, focal adhesion kinase; HBEGF, 
heparin-binding EGF-like growth factor; ID, inhibitor of DNA binding; Igfbp4, insulin-like 
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growth factor binding protein 4; Lox, lysyl oxydase; Orai1, Orai calcium release-activated 
calcium modulator 1; PTHrP, parathyroid hormone related peptide; RANKL, receptor 
activator off nuclear factor kappa-B ligand; Stim1, stromal interactor molecule 1; 
ST6Galnac5, ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl-
galactosaminide alpha-2,6-sialyltransferase 5; Tinagl1, tubulointerstitial nephritis antigen-
like 1. Alternative names for those proteins can be found in the GeneCards database 
(www.genecards.org). Other abbreviations have been introduced in the main text. 
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FIGURE 4. Factors affecting the development of metastatic traits in tumors. Non-
metastatic cancer cells are shown in blue. Metastatic cancer cells are shown in other colors 
to indicate their potential to colonize specific peripheral tissues. Stromal cells are shown in 
yellow.  tn, time involved for the development of step n (depicted arbitrarily).  As indicated 
in the main text, the rate at which metastasis develops can be altered by tumor-intrinsic and 
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extrinsic factors. Extrinsic factors include the genetic background of the primary cell type 
in which the tumor originated (point 1), tumor-stimulated stromal cells, and physiological 
conditions of the individual during tumor development (e.g., inflammation triggered in the 
postpartum mammary gland; point 2). The secretion of factors by the primary tissue that, 
upon arrival and deposition in the peripheral niche, might favor the subsequent survival and 
growth of the extravasated cancer cells, is also depicted (point 3). 
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FIGURE 5. The four main types of movement described for cancer cells are highlighted in 
dark red (see main text): collective 1, collective 2, amoeboid and mesenchymal. Cancer 
cells and non-transformed, tumor associated-fibroblasts are shown in light brown and blue, 
respectively. The signaling routes involved in the migration of cancer cells and the leading 
fibroblast are indicated in the light brown and blue boxes, respectively. Transition of cancer 
cells from the collective 1 to the single cell migration type is mediated by TGFβ-triggered 
EMT. This transition requires the activation of a complex phospho-Smad family protein 4 
(p-Smad4)-dependent transcriptional program that includes the genes encoding the EGF 
tyrosine kinase receptor (EGFR), the adaptor molecule Nedd9 (neural precursor cell 
expressed, developmentally downs-regulated 9 protein, also known as: Casl -Crk-
associated substrate-like-; Hef1; and p105Cas), the myosin phosphatase Rho-interacting 
protein (M-Rip), the Rac1 GEF Farp (FERM: four-point-one, ezrin, radixin, moesin; Rho 
GEF; and pleckstrin domain-containing protein), and the RhoC GTPase [52]. The transition 
from amoeboid to mesenchymal migratory behavior is dependent on a pathway involving 
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Nedd9, the exchange factor Dock3 that catalyzes the activation (via GDP/GTP exchange) 
of the Rac1 GTPase, and the Rac1 downstream effector and cytoskeletal regulator Wave2 
(Wiskott-Aldrich syndrome protein family member 2) [57]. Transition from the 
mesenchymal to the amoeboid type of movement requires the activation of RhoA, which in 
turn promotes the activation of the Rac1-specific ArhGAP2 in a Rock-dependent manner. 
The activation of ArchGAP22 by the RhoA/Rock axis leads to the inactivation of Rac1 by 
hydrolysis of its associated GTP into GDP [34,57]. Although the mechanism of RhoA 
activation remains to be elucidated, a recent study described its induction associated with 
inflammation via the IL6-dependent activation of Janus kinase (Jak) family members [34]. 
RasGRF2 (Ras GDP releasing factor 2), a Ras GEF that binds and blocks the activation of 
the Cdc42 GTPase, has also been implicated in the suppression of amoeboid movement 
[58]. Conversely, the Cdc42-specific Dock10 GEF promotes this type of movement. The 
latter two stages are not depicted in the figure. 
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FIGURE 6. Examples of the new regulatory layers (top) and functions (bottom, shaded) 
associated with EMT regulatory pathways at the epigenetic (purple), translational (light 
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blue) and microRNA (green) level. Transcription factors (brown) and microRNAs (light 
red) are also indicated. The microRNAs that activate the EMT usually target molecules 
implicated in the maintenance of the epithelial structure (e.g., E-cadherin), whereas 
microRNAs that work as inhibitors target pro-metastatic molecules (e.g., RhoC, RhoA, 
transcriptional factors involved in the EMT process). CHFR is a ubiquitin ligase involved 
in regulating mitotic checkpoints and in HDAC degradation. HDAC is a histone 
deacetylase 1 that epigenetically represses E-cadherin expression [92]. LSD1, lysine-
specific demethylase 1 is involved in the NuRD complex [93], a Mi-2/nucleosome 
remodeling and deacetylase complex that controls the expression of elements in the TGFβ 
signaling pathway, and of other molecules involved in the EMT [93]. The Hotair ncRNA is 
involved in the assembly of the chromatin remodeling polycomb repressive complex 2 
(PRC2) [70]. SATB1 (special AT-rich sequence-binding protein 1) is a chromosome 
remodeling factor whose overexpression in breast cancer leads to a large pro-EMT 
transcriptional program [94]. Dab2 (Disabled-2) and Ilei (interleukin-like EMT inducer) are 
two transcripts that lie downstream of EMT and whose translation is inhibited by the 
heterogeneous nuclear ribonucleoprotein E1 (hnRNPE1). This negative control is relieved 
by the Akt2-mediated phosphorylation of hnRNPE1 upon TGFβ stimulation [97]. 
Alternative designations for these proteins can be found in the GeneCards database 
(www.genecards.org). Activation and inactivation steps are shown as arrows and blunted 
lines, respectively. 
